Oris
TM BME (Basement Membrane Extract) coated microplate with the cell seeding stoppers and allowed to adhere for 24h. After 24h, the stopper was removed using the tool provided in the kit.
Cells were rinsed gently and incubated for 12-30h at 37 0 C in RPMI 1640 containing 0.5% FBS.
Mitomycin (5 μg/ml; Sigma) was added to the medium to inhibit proliferation. Cells migrated into the cell-free area and invaded into BME were photographed using a digital spot camera attached to an inverted Nikon phase contrast microscope at 12 and 24h. The assay was performed in duplicates and repeated thrice.
RESULTS

Figure S1
Figure S1: Determination of migration/invasion property of indicted PC3 cells by the Oris cell invasion assay (3D assay). Images were taken by use of an inverted Nikon microscope (Eclipse TE200) with 4X (A-C), 10X (A'-C') and 40X (A"-C") objectives. Representative images of pre-migration/invasion zones at 0h and migrated/invaded zones after 24h (A'-C') are shown. Invaded regions are shown at higher magnification in A"-C". Cells moved through the basement membrane extract (BME) (A'-C') and invaded into the BME (A" and B"). PC3 cells knock down of MMP9 displayed a significant decrease in migration/invasion (C' and C"). Cell migration/invasion into detection zone (towards center) was represented as percent invasion at the bottom of each panel. The results shown are representative of three independent experiments. . Expression of CD44v6 was measured semi-quantitatively via using the intensity of the immunoreactivity of CD44v6. It was calculated using the 0 to 4 tiered scale as shown in Figure S3G . The percentage was calculated based on the staining intensity of cells to CD44v6 protein in 4-tiered scale as shown in the figure G (see description below). 'n' indicates number of cores analyzed. The staining was repeated thrice with similar results.
RESULTS:
Immunohistochemistry analysis for CD44v6 displayed negligible to no staining in the adenocarcinoma isolated at stage 3 ( Figure S3B and B') and stage 4 ( Figure S3C and C'), respectively. CD44v6 expression was stronger in normal tissue and observed in >90% of the luminal epithelial cells (A and A'). Note that intense staining of basolateral plasma membrane of luminal epithelial cells of normal tissue adjacent to prostate cancer at stage 4 (C and C'; indicated by arrows) matches with the staining in normal prostate tissue core (A and A'). Weak staining in the luminal epithelial cells is indicated by an arrow head. Prostatic cancer metastasized to abdominal wall (D) and bone (9E and F) showed weak reactivity for CD44v6 as well (indicated by red arrows). The relative distribution of CD44v6 in immunostained TMA sections containing 24 and 40 cases (in duplicates were semi-quantitatively analyzed by two investigators and provided in Figure S3G . While strong CD44v6 expression was observed in <5% of adenocarcinoma cases, 80-95% of normal cases show strong and very strong reactivity to CD44v6 in prostatic luminal epithelial cells (NM-LEC). We found that CD44v6 reactivity is consistently very low in adenocarcinoma at stage III to IV (<10% stained; ADCA) and in prostate cancer metastasis to bone (<5% stained; METS). Taken together, these observations imply that the switch in expression to CD44s from CD44v6 occur in metastatic cancer.
